HCC almost always grows from a liver already damaged by cirrhosis or chronic hepatitis -- which means the risk is often known before symptoms appear.
The Scale of the Problem
Understanding HCC
Unlike many cancers that appear without warning, hepatocellular carcinoma (HCC) -- the most common type of primary liver cancer -- almost always grows from a liver already damaged by another condition: cirrhosis, chronic hepatitis B, or chronic hepatitis C.
This is both sobering and empowering. If you have cirrhosis or chronic hepatitis, you are in a high-risk group -- but you are also in a group that can be screened every six months, giving the best chance of catching HCC before symptoms appear.
Cholangiocarcinoma (bile duct cancer) and metastatic liver tumours (cancer that has spread from elsewhere) are different diseases and are treated separately.
Who Is Most at Risk
Why Staging Matters
Single tumour <2 cm. No symptoms. Liver function preserved.
1-3 nodules <3 cm or single nodule, no vascular invasion.
Large multifocal HCC. No cancer spread. Liver function OK.
Vascular invasion or spread to lymph nodes/distant organs.
Severe liver dysfunction (Child-Pugh C). Limited options.
Staging uses the Barcelona Clinic Liver Cancer (BCLC) classification system, the international standard for HCC management.
Why HCC Is Often Caught Late
The liver has no pain receptors inside it. A small tumour can grow for months with no sign whatsoever. By the time symptoms appear, the cancer is usually at an intermediate or advanced stage.
This is why six-monthly ultrasound + AFP (alpha-fetoprotein) testing is recommended for all cirrhosis patients and chronic HBV carriers. It is the only reliable way to detect HCC at a curable stage.
Symptoms -- Usually Late Stage
If you have cirrhosis or chronic hepatitis and notice any of the above, seek evaluation immediately -- do not wait for a scheduled check-up.
Treatment Options
Early-stage HCC can be cured. The goal shifts from cure to disease control at later stages. Dr. Sahota's team evaluates each patient across all relevant criteria before recommending a path.
Removal of the tumour and a margin of healthy tissue. Best for patients with well-preserved liver function and a single tumour without vascular invasion.
Radiofrequency ablation (RFA) destroys small tumours with heat. TACE (trans-arterial chemoembolisation) cuts blood supply to larger tumours. Used for intermediate stage or as a bridge to transplant.
Sorafenib and atezolizumab-bevacizumab are first-line systemic agents for BCLC-C (advanced) HCC. They slow tumour growth and extend survival. Immunotherapy combinations are improving outcomes significantly.
Why Patients Choose LiverGuru
Whether you have a known risk factor, a suspicious scan result, or symptoms that worry you -- early evaluation is the single most important step. Dr. Sahota's team will assess your situation and recommend the right path.
Or reach us on WhatsApp: +91 75892 27787